theMednetRegister

Nephrology

Advanced Heart Failure and Transplant   

Questions discussed in this category

What is your approach to initiating spironolactone in patients with end stage kidney disease and heart failure?
4 Answers available
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
2 Answers available
How do you use NT-proBNP in patients with chronic kidney disease or end-stage kidney disease, given that these conditions can affect NT-proBNP levels?
1 Answer available
How do you weigh the benefit of urinary catheter placement for strict I/O measurement with the risk of avoidable CAUTI?
How does your approach vary by indication (critical illness, acute renal failure, hyponatremia, diuresis, etc.)?
1 Answer available
What is your approach to weaning dialysis in a patient with AKI on CKD and CHF who now has resolved AKI but a history of recurrent episodes of decompensated heart failure?
1 Answer available
Do you recommend avoiding ESAs in ESKD patients with heart failure who require a left ventricular assist device?
1 Answer available
For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?
1 Answer available
Are recurrent UTIs a contraindication to SGLT2i use?
4 Answers available
Below what ejection fraction would you avoid referral for AV access creation in a patient with advanced CKD and heart failure with reduced ejection fraction?
1 Answer available
Do you recommend checking urine sodium 2 hours after loop diuretic administration to determine the need for dose adjustment in a patient with acute decompensated heart failure?
1 Answer available
Would you consider adding an SGLT2 inhibitor to augment diuresis in patients with worsening renal function presenting with acute decompensated heart failure and AKI on CKD?
1 Answer available
Do you use tolvaptan for management of hyponatremia related to heart failure given the side effect profile and lack of mortality benefit seen in a previous trial?
The EVEREST Outcome trial (Konstam et al., PMID 17384437)
1 Answer available


Papers discussed in this category

Kidney international, 2019-04
Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.
Kidney360, 2023 Feb 10
Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial.
Frontiers in medicine, 2022 Mar 17
Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials.
The international journal of cardiovascular imaging, 2021 Feb 05
The effect of spironolactone on diastolic function in haemodialysis patients.
Journal of clinical hypertension (Greenwich, Conn.), 2015 Jul 30
Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.
Kidney international, 2019 Jan 31
A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.
The New England journal of medicine, 2014-09-11
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
Circulation, 2022 Apr 01
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
The New England journal of medicine, 2019 Sep 19
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
The New England journal of medicine, 2020 Aug 28
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
JACC. Heart failure, 2024 Aug 31
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.

Related Topics in Nephrology

Copyright © 2025 theMednet
All Rights Reserved.